Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development: 2017-2025

Historic Research & Development for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to $90.5 million.

  • Crinetics Pharmaceuticals' Research & Development rose 46.13% to $90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.6 million, marking a year-over-year increase of 43.07%. This contributed to the annual value of $240.2 million for FY2024, which is 42.50% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Research & Development of $90.5 million as of Q3 2025, which was up 12.66% from $80.3 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Research & Development high stood at $90.5 million for Q3 2025, and its period low was $17.6 million during Q1 2021.
  • Its 3-year average for Research & Development is $59.6 million, with a median of $58.3 million in 2024.
  • Data for Crinetics Pharmaceuticals' Research & Development shows a peak YoY soared of 80.56% (in 2022) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Research & Development (Quarterly) stood at $20.5 million in 2021, then surged by 80.56% to $37.0 million in 2022, then rose by 23.22% to $45.6 million in 2023, then soared by 46.04% to $66.6 million in 2024, then soared by 46.13% to $90.5 million in 2025.
  • Its Research & Development stands at $90.5 million for Q3 2025, versus $80.3 million for Q2 2025 and $76.2 million for Q1 2025.